Actively Recruiting
Effects of Palynziq Treatment on Diet, Brain Health, and Nutrition in Adults with Phenylketonuria PKU
Led by Emory University · Updated on 2026-01-14
45
Participants Needed
2
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Phenylketonuria PKU is a genetic disorder that affects the bodys ability to process the amino acid phenylalanine, leading to harmful buildup in the blood and brain. This research is focused on studying the effects of Palynziq, a new FDA-approved drug, on patients with PKU. The study aims to understand how Palynziq impacts diet quality, neurological health, nutritional status, and metabolic changes over time. Participants with PKU who are starting or have recently started Palynziq therapy will be observed for up to three years, with an option to join a sub-study extending the observation for up to five more years. Palynziq is given as an injection under medical supervision following specific safety protocols. Patients will continue their clinical care by submitting blood samples and keeping dietary records as part of their treatment monitoring. During the study, researchers will track changes in protein intake, nutritional markers, cognitive function, sleep quality, emotional health, body composition, and energy use. Assessments include blood tests, questionnaires, and physical measurements from baseline through 12 months post-treatment response, and longer-term follow-up in the sub-study. This allows detailed understanding of how Palynziq therapy affects patients health and quality of life over time.
CONDITIONS
Brief Title
Nutritional Impacts of Palynziq on Patients With Phenylketonuria (PKU)
Research Team
R
Rani Singh, PhD, RDN, LD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here